Spero Therapeutics, Inc. 8-K

What Happened

• On May 13, 2026, Spero Therapeutics, Inc. (SPRO) announced its quarterly results for the period ended March 31, 2026 by issuing a press release. The company furnished that press release as Exhibit 99.1 to a Current Report on Form 8‑K (Item 2.02: Results of Operations and Financial Condition).

Key Details

• Filing date: May 13, 2026 (Form 8‑K).
• Reporting period: Quarter ended March 31, 2026.
• Disclosure format: Results disclosed via a press release furnished as Exhibit 99.1 to the 8‑K.
• The filing also includes the Inline XBRL cover page (Exhibit 104) embedded in the submission.

Why It Matters

• This 8‑K is the company’s official update on its quarterly earnings and financial condition; the press release will contain the specific earnings, revenue, cash position, and any management commentary that investors use to assess near‑term performance.
• Investors should read the furnished press release (Exhibit 99.1) for the detailed quarterly results and any forward‑looking statements or guidance. This filing does not indicate any executive changes, mergers, or bankruptcy—only the release of quarterly results.